292 related articles for article (PubMed ID: 17241416)
1. Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines.
Carruthers A; Carruthers J; Flynn TC; Leong MS
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S60-8. PubMed ID: 17241416
[TBL] [Abstract][Full Text] [Related]
2. Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinkles.
Sadick NS
Dermatol Surg; 2003 May; 29(5):501-7; discussion 507. PubMed ID: 12752518
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines.
Ascher B; Zakine B; Kestemont P; Baspeyras M; Bougara A; Santini J
J Am Acad Dermatol; 2004 Aug; 51(2):223-33. PubMed ID: 15280841
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Moore D
J Cosmet Laser Ther; 2002 Mar; 4(1):15-8. PubMed ID: 12079632
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study.
Sadick NS; Faacs
Dermatol Surg; 2002 Sep; 28(9):817-21. PubMed ID: 12269875
[TBL] [Abstract][Full Text] [Related]
6. RimabotulinumtoxinB vs. onabotulinumtoxinA for the treatment of forehead lines: an evaluator-blind, randomized, pilot study.
Lee DH; Kang SM; Feneran A; Youn CS; Kim JK; Cho S; Won CH; Chang SE; Lee MW; Choi JH; Moon KC
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e1-7. PubMed ID: 23030660
[TBL] [Abstract][Full Text] [Related]
7. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
Carruthers JD; Lowe NJ; Menter MA; Gibson J; Eadie N;
Plast Reconstr Surg; 2003 Sep; 112(4):1089-98. PubMed ID: 12973229
[TBL] [Abstract][Full Text] [Related]
8. Dosing, efficacy and safety plus the use of computerized photography for botulinum toxins type A for upper facial lines.
Lowe NJ; Shah A; Lowe PL; Patnaik R
J Cosmet Laser Ther; 2010 Apr; 12(2):106-11. PubMed ID: 20151785
[TBL] [Abstract][Full Text] [Related]
9. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?
Carruthers A; Carruthers J; Cohen J
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S97-104. PubMed ID: 17241422
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.
Monheit G; Carruthers A; Brandt F; Rand R
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S51-9. PubMed ID: 17241415
[TBL] [Abstract][Full Text] [Related]
11. Eyebrow height after botulinum toxin type A to the glabella.
Carruthers A; Carruthers J
Dermatol Surg; 2007 Jan; 33(1 Spec No.):S26-31. PubMed ID: 17241411
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
Dessy LA; Fallico N; Mazzocchi M; Scuderi N
Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
[TBL] [Abstract][Full Text] [Related]
14. Botulinum B treatment of the glabellar and frontalis regions: a dose response analysis.
Spencer JM; Gordon M; Goldberg DJ
J Cosmet Laser Ther; 2002 Mar; 4(1):19-23. PubMed ID: 12079633
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.
Carruthers JA; Lowe NJ; Menter MA; Gibson J; Nordquist M; Mordaunt J; Walker P; Eadie N;
J Am Acad Dermatol; 2002 Jun; 46(6):840-9. PubMed ID: 12063480
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.
Baumann L; Slezinger A; Halem M; Vujevich J; Martin LK; Black L; Bryde J
Int J Dermatol; 2005 May; 44(5):418-24. PubMed ID: 15869543
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines.
Kim JE; Song EJ; Choi GS; Lew BL; Sim WY; Kang H
Plast Reconstr Surg; 2015 Mar; 135(3):732-741. PubMed ID: 25719692
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study.
Won CH; Lee HM; Lee WS; Kang H; Kim BJ; Kim WS; Lee JH; Lee DH; Huh CH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):171-8. PubMed ID: 23301821
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A.
Alster TS; Lupton JR
Dermatol Surg; 2003 May; 29(5):516-8. PubMed ID: 12752520
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of EB-001, a Novel Type E Botulinum Toxin, in Subjects with Glabellar Frown Lines: Results of a Phase 2, Randomized, Placebo-Controlled, Ascending-Dose Study.
Yoelin SG; Dhawan SS; Vitarella D; Ahmad W; Hasan F; Abushakra S
Plast Reconstr Surg; 2018 Dec; 142(6):847e-855e. PubMed ID: 30489516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
